Skip to main content
OpenTrials
Completed

NCT Number: NCT02058654

A Clinical Study to Investigate the Effects of Creatine Supplementation on Muscle Energetics and Cognitive Function in Young Healthy Male Athletes and an Ageing Population

This study will examine the impact of creatine supplementation on muscle function and cognitive performance in young and older subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

GSK Investigational Site

London, NW10 7EW, United Kingdom

About this study

This is a randomised, double-blind study of the effects of creatine supplementation on muscle energetics and cognitive function, using 31P-MRS and fMRI. 31P-MRS data will be acquired continuously during exercise phase and in the post-exercise metabolic recovery phase. Participants will undergo a fMRI scan of the brain to record changes in the blood oxygen level dependent (BOLD) signal during a series of cognitive tests. In addition, participants will undergo a resting state BOLD scan and a structural MRI scan for localization of brain regions.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy volunteer: Group 1: male; Group 2: male or female.
  • Aged 18-35 years (Group 1), or 50-70 years (Group 2).
  • Dietary protein intake at or near the current recommended daily amount (0.75 to 0.85 g protein/kg/day).
  • Participation in regular physical activity (aerobic and resistance training) 2-3 times a week for at least 6 months before the study starts (Group 1 only).
  • Willingness to maintain a stable lifestyle throughout the study.

Exclusion criteria

  • Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the volunteer.
  • Presence of acute or chronic illness or history of chronic illness sufficient to invalidate the volunteer's participation in the trial or make it unnecessarily hazardous.
  • Impaired endocrine, thyroid, hepatic, respiratory, neurological, or renal function, diabetes mellitus, cardiovascular disease, coagulation disorder, autoimmune disease, phenylketonuria, hyperlipidaemia, or history of any psychotic mental illness.
  • Any impairment affecting mobility and muscle metabolism of the lower limbs (such as arthritis).
  • Surgery (eg stomach bypass) or medical condition that might affect absorption of supplements.
  • Inability to complete the structured exercise program.
  • Blood pressure and heart rate in seated position at the screening examination outside the ranges 90-140 mm Hg systolic, 40-90 mm Hg diastolic; heart rate 35-100 beats/min (Group 1) or 40-100 beats/min (Group 2).
  • Metal implants that may affect the MRI scan, eg gold tooth or other metal dental devices (normal dental fillings are allowed), pacemaker, mechanical heart valve, replacement joint, shrapnel. If any metal in the body is identified, the investigators will make a decision, as to whether the subject should participate in the study.
  • History of claustrophobia or subject feels unable to lie still on their back for a period of 90 mins in the MRI scanner, or subject unable to perform the required muscle exercise in the MRI scanner.

Treatment and study plan

Creatine

Drug

Creatine powder (5 g)

Placebo

Drug

Bulking agent powder (5 g)

Primary outcomes

  1. PCr Concentration (at rest)

    Time frame: Baseline to Day 3, 7 and 14

    Change in PCr concentration (at rest), as measured by 31P- MRS on the calf. Static MRS will be acquired at rest up to 2 min.

Secondary outcomes

  1. PCr concentration during recovery

    Time frame: Baseline to Day 3, 7, and 14

    Change in PCr concentration (during recovery) as measured by 31P- MRS on the calf. Dynamic MRS will be acquired with the patient at rest for up to 20 min.

  2. Change in PCr from rest to recovery

    Time frame: Baseline to Day 3, 7, and 14

    Change in PCr concentration (from rest to recovery) as measured by 31P- MRS on the calf.

  3. PCr recovery rate (PCr(T1/2))

    Time frame: Baseline to Day 3, 7 and 14

    Measured by 31P-MRS on the leg

  4. ADP recovery rate (ADP (T1/2))

    Time frame: Baseline to Day 3, 7 and 14

    Measured by 31P-MRS on the leg

  5. pH at the end of pedal test, or at the time of voluntary cessation (Post-pedal test pH)

    Time frame: Baseline to Day 3, 7 and 14

    Measured by 31P-MRS on the leg

  6. Lowest pH measured during pedal test or recovery (Minimum pH)

    Time frame: Baseline to Day 3, 7 and 14

    Measured by 31P-MRS on the leg

  7. BOLD signal in the brain

    Time frame: Baseline to Day 14

    Change in BOLD signal, as measured by an fMRI scan of the brain. Data may be examined at both a whole-brain and region of interest (ROI) level, with ROIs defined either anatomically or based on clusters derived from the group data.

  8. Cognitive function

    Time frame: Baseline to Day 14

    A standard test battery will be used to examine changes in behavioural measures of cognition, including speed of processing (detection task), attention/vigilance (identification task), working memory, visual learning and memory, and reasoning and problem solving. In addition, a visual analogue scales (VAS) will be used to assess subjective mood state.

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

A Randomised, Double-blind, Study to Investigate the Effects of Creatine Supplementation on Muscle Energetics and Cognitive Function in Young Healthy Male Athletes and an Ageing Population Using Phosphorus-31 Magnetic Resonance Spectroscopy (31P MRS) and Functional Magnetic Resonance Imaging (fMRI)

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Feb 10, 2014
Registry last updated
Mar 23, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.